Codexis (CDXS) Revenue & Revenue Breakdown
Codexis Revenue Highlights
Latest Revenue (Y)
$70.14M
Latest Revenue (Q)
$17.07M
Main Segment (Y)
Enzyme Product
Main Geography (Y)
Asia Pacific
Codexis Revenue by Period
Codexis Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $70.14M | -49.39% |
| 2022-12-31 | $138.59M | 32.30% |
| 2021-12-31 | $104.75M | 51.69% |
| 2020-12-31 | $69.06M | 0.87% |
| 2019-12-31 | $68.46M | 12.98% |
| 2018-12-31 | $60.59M | 21.13% |
| 2017-12-31 | $50.02M | 2.43% |
| 2016-12-31 | $48.84M | 16.82% |
| 2015-12-31 | $41.80M | 18.40% |
| 2014-12-31 | $35.31M | 10.60% |
| 2013-12-31 | $31.92M | -63.85% |
| 2012-12-31 | $88.30M | -28.71% |
| 2011-12-31 | $123.86M | 15.65% |
| 2010-12-31 | $107.10M | 29.18% |
| 2009-12-31 | $82.91M | 64.25% |
| 2008-12-31 | $50.48M | 99.26% |
| 2007-12-31 | $25.33M | 108.90% |
| 2006-12-31 | $12.13M | - |
Codexis generated $70.14M in revenue during NA 2023, up -49.39% compared to the previous quarter, and up 115.76% compared to the same period a year ago.
Codexis Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $17.07M | -35.72% |
| 2023-12-31 | $26.56M | 186.31% |
| 2023-09-30 | $9.28M | -56.49% |
| 2023-06-30 | $21.32M | 64.25% |
| 2023-03-31 | $12.98M | -57.26% |
| 2022-12-31 | $30.38M | -11.88% |
| 2022-09-30 | $34.47M | -10.25% |
| 2022-06-30 | $38.41M | 8.68% |
| 2022-03-31 | $35.34M | 44.24% |
| 2021-12-31 | $24.50M | -33.37% |
| 2021-09-30 | $36.77M | 44.46% |
| 2021-06-30 | $25.45M | 41.15% |
| 2021-03-31 | $18.03M | -14.27% |
| 2020-12-31 | $21.03M | 14.41% |
| 2020-09-30 | $18.39M | 22.84% |
| 2020-06-30 | $14.97M | 2.02% |
| 2020-03-31 | $14.67M | -21.34% |
| 2019-12-31 | $18.65M | -14.86% |
| 2019-09-30 | $21.91M | 77.82% |
| 2019-06-30 | $12.32M | -20.95% |
| 2019-03-31 | $15.58M | -3.02% |
| 2018-12-31 | $16.07M | -5.18% |
| 2018-09-30 | $16.95M | 25.17% |
| 2018-06-30 | $13.54M | -3.59% |
| 2018-03-31 | $14.04M | -35.36% |
| 2017-12-31 | $21.72M | 117.57% |
| 2017-09-30 | $9.98M | -3.51% |
| 2017-06-30 | $10.35M | 29.81% |
| 2017-03-31 | $7.97M | -20.04% |
| 2016-12-31 | $9.97M | -32.96% |
| 2016-09-30 | $14.87M | -7.07% |
| 2016-06-30 | $16.00M | 100.13% |
| 2016-03-31 | $8.00M | -30.99% |
| 2015-12-31 | $11.59M | -33.42% |
| 2015-09-30 | $17.40M | 189.15% |
| 2015-06-30 | $6.02M | -11.47% |
| 2015-03-31 | $6.80M | -52.10% |
| 2014-12-31 | $14.19M | 89.92% |
| 2014-09-30 | $7.47M | 13.73% |
| 2014-06-30 | $6.57M | -7.12% |
| 2014-03-31 | $7.07M | -25.73% |
| 2013-12-31 | $9.53M | 141.57% |
| 2013-09-30 | $3.94M | -43.46% |
| 2013-06-30 | $6.97M | -39.26% |
| 2013-03-31 | $11.48M | 45.11% |
| 2012-12-31 | $7.91M | -69.96% |
| 2012-09-30 | $26.34M | 14.98% |
| 2012-06-30 | $22.91M | -26.42% |
| 2012-03-31 | $31.14M | -7.04% |
| 2011-12-31 | $33.49M | 0.63% |
| 2011-09-30 | $33.28M | 27.74% |
| 2011-06-30 | $26.05M | -16.04% |
| 2011-03-31 | $31.03M | 4.10% |
| 2010-12-31 | $29.81M | 9.95% |
| 2010-09-30 | $27.11M | 10.76% |
| 2010-06-30 | $24.48M | -4.75% |
| 2010-03-31 | $25.70M | 6.03% |
| 2009-12-31 | $24.24M | 20.82% |
| 2009-09-30 | $20.06M | 4.50% |
| 2009-06-30 | $19.20M | -1.09% |
| 2009-03-31 | $19.41M | 4.37% |
| 2008-12-31 | $18.60M | 122.09% |
| 2008-03-31 | $8.37M | 78.02% |
| 2007-03-31 | $4.70M | - |
Codexis generated $17.07M in revenue during Q1 2024, up -35.72% compared to the previous quarter, and up 56.21% compared to the same period a year ago.
Codexis Revenue Breakdown
Codexis Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|---|---|
| Enzyme Product | $75.40M | $1.70M | - | - | - |
| Research and Development Revenue | $1.61M | $3.05M | $2.30M | $57.00K | $2.73M |
| Product Sales | $29.00M | $3.28M | $2.49M | $1.99M | $2.20M |
| Sitagliptin Enzyme | $1.60M | $2.80M | - | - | - |
| Service | - | $34.10M | $38.84M | $38.99M | $35.00M |
Codexis's latest annual revenue breakdown by segment (product or service), as of Dec 22: Enzyme Product (70.07%), Product Sales (26.95%), Research and Development Revenue (1.50%), and Sitagliptin Enzyme (1.49%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research And Development Revenue | $7.52M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Product Sales | $10.49M | $21.38M | $3.05M | $2.97M | $16.98M | $2.84M | $1.98M | $2.82M | $12.21M | $1.99M | $2.83M | $2.05M | $4.88M | - | - | - | - | - | - | - |
| Research and Development Revenue | - | $3.88M | $1.54M | $7.50M | $7.08M | $1.47M | $2.33M | $2.10M | $7.52M | $3.36M | $3.50M | $1.98M | $8.82M | $2.07M | $2.21M | $6.48M | $13.77M | $1.29M | $5.57M | $1.32M |
| Product | - | $18.68M | $19.10M | $8.37M | $3.60M | $2.50M | $5.30M | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Enzyme Product | - | - | - | - | $19.80M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Codexis's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Product Sales (58.24%), and Research And Development Revenue (41.76%).
Codexis Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|---|---|
| Asia Pacific | $65.05M | $61.09M | - | - | - |
| EMEA | $56.54M | $20.19M | $19.26M | $37.13M | $22.36M |
| Americas | $17.00M | $23.48M | $24.35M | $13.04M | $15.37M |
| APAC | - | - | $25.45M | $18.29M | $22.86M |
Codexis's latest annual revenue breakdown by geography, as of Dec 22: Asia Pacific (46.94%), EMEA (40.80%), and Americas (12.27%).
Quarterly Revenue by Country
| Country | Mar 24 | Sep 23 | Dec 21 | Sep 21 | Dec 19 | Jun 18 | Mar 18 |
|---|---|---|---|---|---|---|---|
| EMEA | $2.57M | $3.19M | $12.46M | $1.44M | $1.68M | - | - |
| APAC | $7.26M | $1.81M | $2.77M | - | - | - | - |
| Americas | $7.24M | $4.28M | $3.42M | - | - | - | - |
| Asia Pacific | - | - | $16.56M | $24.27M | - | - | - |
Codexis's latest quarterly revenue breakdown by geography, as of Mar 24: APAC (42.51%), Americas (42.43%), and EMEA (15.06%).
Codexis Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| KYMR | Kymera Therapeutics | $78.59M | $10.29M |
| NRIX | Nurix Therapeutics | $76.99M | $12.09M |
| CDXS | Codexis | $70.14M | $17.07M |
| FHTX | Foghorn Therapeutics | $34.16M | $6.89M |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| KZR | Kezar Life Sciences | $7.00M | - |
| GBIO | Generation Bio | $5.90M | $4.06M |
| IPSC | Century Therapeutics | $2.23M | $771.00K |
| STTK | Shattuck Labs | $1.66M | $1.61M |
| LYEL | Lyell Immunopharma | $130.00K | $3.00K |
| CGEM | Cullinan Oncology | - | - |
| NGM | NGM Biopharmaceuticals | - | $165.00K |
| NKTX | Nkarta | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| NUVB | Nuvation Bio | - | $1.44M |
CDXS Revenue FAQ
What is Codexis’s yearly revenue?
Codexis's yearly revenue for 2023 was $70.14M, representing a decrease of -49.39% compared to 2022. The company's yearly revenue for 2022 was $138.59M, representing an increase of 32.30% compared to 2021. CDXS's yearly revenue for 2021 was $104.75M, representing an increase of 51.69% compared to 2020.
What is Codexis’s quarterly revenue?
Codexis's quarterly revenue for Q1 2024 was $17.07M, a -35.72% decrease from the previous quarter (Q4 2023), and a 31.51% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $26.56M, a 186.31% increase from the previous quarter (Q3 2023), and a -12.56% decrease year-over-year (Q4 2022). CDXS's quarterly revenue for Q3 2023 was $9.28M, a -56.49% decrease from the previous quarter (Q2 2023), and a -73.09% decrease year-over-year (Q3 2022).
What is Codexis’s revenue growth rate?
Codexis's revenue growth rate for the last 3 years (2021-2023) was -33.04%, and for the last 5 years (2019-2023) was 2.46%.
What are Codexis’s revenue streams?
Codexis's revenue streams in c 22 are Enzyme Product, Research and Development Revenue, Product Sales, and Sitagliptin Enzyme. Enzyme Product generated $75.4M in revenue, accounting 70.07% of the company's total revenue, up 4335.29% year-over-year. Research and Development Revenue generated $1.61M in revenue, accounting 1.50% of the company's total revenue, down -47.18% year-over-year. Product Sales generated $29M in revenue, accounting 26.95% of the company's total revenue, up 783.75% year-over-year. Sitagliptin Enzyme generated $1.6M in revenue, accounting 1.49% of the company's total revenue, down -42.86% year-over-year.
What is Codexis’s main source of revenue?
For the fiscal year ending Dec 22, the largest source of revenue of Codexis was Enzyme Product. This segment made a revenue of $75.4M, representing 70.07% of the company's total revenue.